These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23537343)

  • 1. CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy.
    Mia-Jan K; Jung SY; Kim IY; Oh SS; Choi E; Chang SJ; Kang TY; Cho MY
    BMC Cancer; 2013 Mar; 13():166. PubMed ID: 23537343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma.
    Oliver JA; Ortiz R; Melguizo C; Alvarez PJ; Gómez-Millán J; Prados J
    BMC Cancer; 2014 Jul; 14():511. PubMed ID: 25015560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
    Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
    J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients.
    Artells R; Moreno I; Díaz T; Martínez F; Gel B; Navarro A; Ibeas R; Moreno J; Monzó M
    Eur J Cancer; 2010 Feb; 46(3):642-9. PubMed ID: 20005089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.
    Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A
    Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer.
    Kim ST; Sohn I; DO IG; Jang J; Kim SH; Jung IH; Park JO; Park YS; Talasaz A; Lee J; Kim HC
    Cancer Genomics Proteomics; 2014; 11(5):259-66. PubMed ID: 25331798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of CTCs and CSCs of tumor drainage vein blood in Dukes' stage B and C colorectal cancer patients.
    Shimada R; Iinuma H; Akahane T; Horiuchi A; Watanabe T
    Oncol Rep; 2012 Apr; 27(4):947-53. PubMed ID: 22267181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status.
    Shikina A; Shinto E; Hashiguchi Y; Ueno H; Naito Y; Okamoto K; Kubo T; Fukazawa S; Yamamoto J; Hase K
    Jpn J Clin Oncol; 2014 Jan; 44(1):42-8. PubMed ID: 24244031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.
    Jing F; Kim HJ; Kim CH; Kim YJ; Lee JH; Kim HR
    Int J Oncol; 2015 Apr; 46(4):1582-8. PubMed ID: 25625240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
    Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
    Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
    Stanisavljević L; Myklebust MP; Leh S; Dahl O
    Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD133 mRNA expression and microsatellite instability in colorectal carcinoma.
    Huh JW; Park YS; Lee JH; Kim HR; Shin MG; Kim YJ
    J Surg Oncol; 2010 Dec; 102(7):765-70. PubMed ID: 20872808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD133 expression predicts for non-response to chemotherapy in colorectal cancer.
    Ong CW; Kim LG; Kong HH; Low LY; Iacopetta B; Soong R; Salto-Tellez M
    Mod Pathol; 2010 Mar; 23(3):450-7. PubMed ID: 20081809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoter hypermethylation and loss of CD133 gene expression in colorectal cancers.
    Jeon YK; Kim SH; Choi SH; Kim KH; Yoo BC; Ku JL; Park JG
    World J Gastroenterol; 2010 Jul; 16(25):3153-60. PubMed ID: 20593500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A gene signature distinguishing CD133hi from CD133- colorectal cancer cells: essential role for EGR1 and downstream factors.
    Ernst A; Aigner M; Nakata S; Engel F; Schlotter M; Kloor M; Brand K; Schmitt S; Steinert G; Rahbari N; Koch M; Radlwimmer B; Weitz J; Lichter P
    Pathology; 2011 Apr; 43(3):220-7. PubMed ID: 21436631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of CD133 based on microsatellite instability status in human colorectal cancer.
    Park JJ; Kwon JH; Oh SH; Choi J; Moon CM; Ahn JB; Hong SP; Cheon JH; Kim TI; Kim H; Kim WH
    Mol Carcinog; 2014 Feb; 53 Suppl 1():E1-10. PubMed ID: 23065858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment.
    Lönnroth C; Andersson M; Nordgren S; Lundholm K
    Int J Oncol; 2012 Jul; 41(1):15-23. PubMed ID: 22552364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy.
    Pohl A; El-Khoueiry A; Yang D; Zhang W; Lurje G; Ning Y; Winder T; Hu-Lieskoven S; Iqbal S; Danenberg KD; Kahn M; Teo JL; Shriki J; Stebbing J; Lenz HJ
    Pharmacogenomics J; 2013 Apr; 13(2):173-80. PubMed ID: 22231565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients.
    Takahashi S; Kamiyama T; Tomaru U; Ishizu A; Shida T; Osaka M; Sato Y; Saji Y; Ozaki M; Todo S
    Oncol Rep; 2010 Nov; 24(5):1201-12. PubMed ID: 20878111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
    Metellus P; Nanni-Metellus I; Delfino C; Colin C; Tchogandjian A; Coulibaly B; Fina F; Loundou A; Barrie M; Chinot O; Ouafik L; Figarella-Branger D
    Ann Surg Oncol; 2011 Oct; 18(10):2937-45. PubMed ID: 21479688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.